IntelGenx Grants Options to IR Firm

January 22, 2010

SAINT LAURENT, QUEBEC, Jan 22, 2010 (Marketwire via COMTEX) -- IntelGenx Technologies Corp. ("IntelGenx") (IGX)(US:IGXT) announced today the grant of 50,000 options to purchase common shares of IntelGenx to SectorSpeak Inc., its Canadian Investor Relations firm. The options will vest 50% on the first, and 50% on the second, anniversary of the grant and are exercisable at CAD$0.50 for a period of three years. The grant of options is subject to acceptance by the TSX Venture Exchange.

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp. is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx's research and development pipeline includes products for the treatment of pain, hypertension, osteoarthritis and depressive disorders. More information is available about the company at www.intelgenx.com.

SOURCE: IntelGenx Technologies Corp.

IntelGenx Technologies Corp.
Dr. Horst G. Zerbe
President and CEO
514-331-7440 (ext. 201)
514-331-0436 (FAX) (FAX)
horst@intelgenx.com
www.intelgenx.com